Cover Image

Pembrolizumab Versus Placebo as second-line therapy in patients From Asia with advanced hepatocellular carcinoma: A randomized, double-blind, phase III trial

We evaluated the efficacy and safety of pembrolizumab in patients from Asia with previously treated advanced hepatocellular carcinoma (HCC).METHODSIn a double-blind, phase III trial, 453 patients with advanced HCC and progression during or after treatment with or intolerance to sorafenib or oxalipla...

Full description

Saved in:
Bibliographic Details
Main Authors: Qin, Shukui, Chen, Zhendong, Fang, Weijia, Ren, Zhenggang, Xu, Ruocai, Ryoo, Baek-Yeol, Meng, Zhiqiang, Bai, Yuxian, Chen, Xiaoming, Liu, Xiufeng, Xiao, Juxiang, Ho, Gwo Fuang, Mao, Yimin, Wang, Xin, Ying, Jieer, Li, Jianfeng, Zhong, Wenyan, Zhou, Yu, Siegel, Abby B., Hao, Chunyi
Format: Article
Published: American Society of Clinical Oncology 2023
Subjects:
R Medicine
RA Public aspects of medicine
Online Access:http://eprints.um.edu.my/38540/
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://eprints.um.edu.my/38540/

Similar Items